背景:有效的癌症筛查和治疗监测对癌症患者至关重要。虽然泌尿生殖系统癌症有很高的复发率,当被诊断时,患者及时接受手术。我们试图探索敏感和无创筛查和术后复发监测方法,如循环肿瘤细胞(CTC)或肿瘤易感基因检测,以确定它们是否适合泌尿生殖系统癌症。
方法:我们采用了多种检测方法。采用富集-免疫荧光原位杂交(SE-iFISH)检测患者外周血中的CTC,和AgenaBioscienceMassARRAY用于检测尿液细胞肿瘤易感基因中的单核苷酸多态性(SNP)。
结果:在我们的研究中,在26例泌尿生殖系统癌症患者中,CTC的阳性率为76.92%,CTC的数量与癌症分期一致。在监测膀胱癌(BC)复发时,CTC比尿细胞学更普遍(66.67%vs.41.67%)。令我们惊讶的是,尿细胞XPC(rs2228001,A2815C)和XRCC1(rs25487,G1196A)多态性在癌症患者中特别发现,但在炎症患者或健康个体中未发现.XPC多态性(rs2228001,A2815C)率为30.77%,40%,50%在膀胱癌中,肾癌,前列腺癌患者,分别,XRCC1(rs25487,G1196A)为3.85%,20%,25%,分别。
结论:作为一种常见的生物标志物,CTC在癌症筛查和监测中表现出显著的性能。包含CTC和XPC(rs2228001,A2815C)和XRCC1(rs25487,G1196A)多态性的非侵入性组显示出较高的敏感性(阳性率:92.86%),适用于泌尿生殖系统癌症筛查。
BACKGROUND: Valid cancer screening and treatment monitoring are critical for cancer patients. Although genitourinary system cancers have a high recurrence rate, when diagnosed, patients undergo surgery promptly. We sought to explore sensitive and noninvasive screening and postoperative recurrence monitoring methods, such as circulating tumor cells (CTCs) or tumor susceptibility gene detection, to determine their appropriateness for genitourinary system cancers.
METHODS: We adopted multiple detection methods. Enrichment-immunofluorescence in situ hybridization (SE-iFISH) was employed to detect CTCs from the peripheral blood of patients, and Agena Bioscience MassARRAY was used to detect single-nucleotide polymorphisms (SNPs) in tumor susceptibility genes from urine cells.
RESULTS: In our research, CTCs showed a 76.92% positivity rate among 26 genitourinary system cancer patients, and the number of CTCs was consistent with the stage of cancer. In monitoring for bladder cancer (BC) recurrence, CTCs were more prevalent than urine cytology (66.67% vs. 41.67%). To our surprise, urine cellular XPC (rs2228001, A2815C) and
XRCC1 (rs25487, G1196A) polymorphisms were specifically found in cancer patients but not in patients with inflammation or in healthy individuals. XPC polymorphism (rs2228001, A2815C) rates were 30.77%, 40%, and 50% in bladder cancer, renal carcinoma, and prostate cancer patients, respectively, and those for
XRCC1 (rs25487, G1196A) were 3.85%, 20%, and 25%, respectively.
CONCLUSIONS: As a common biomarker, CTCs showed remarkable performance in cancer screening and monitoring. The noninvasive panel comprising CTCs and XPC (rs2228001, A2815C) and
XRCC1 (rs25487, G1196A) polymorphisms showed high sensitivity (positive rate: 92.86%) and is suitable for genitourinary system cancer screening.